Alain Cosmidis
Lyon College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alain Cosmidis.
Laryngoscope | 2008
Olivier Choussy; C. Ferron; Pierre-Olivier Vedrine; Bruno Toussaint; Béatrice Liétin; P. Marandas; E. Babin; Dominique De Raucourt; Emile Reyt; Alain Cosmidis; Marc Makeiff; Danièle Dehesdin
Objective: To determine risk factors and evaluate the treatment of ethmoid adenocarcinoma. Epidemiologic data were recorded and compared with the literature.
European Archives of Oto-rhino-laryngology | 2004
Alain Cosmidis; Jean-Pierre Rame; Olivier Dassonville; S. Temam; François Massip; Gilles Poissonnet; Marc Poupart; P. Marandas; Dominique De Raucourt
The aim of this study is to show that surgical treatment of early-stage squamous cell carcinomas of the oropharynx gives identical, if not better, oncological results than the classic radiotherapy treatment in terms of locoregional control and survival. Fifty-three patients (32 T1, 21 T2, all N0) were operated on during the years 1995–2000. Surgical treatment consisted in a resection by the transoral approach in 43 patients (81.13%); ten patients (18.87%) benefited from a pharyngectomy with (seven) or without (three) mandibular resection. A level I to V selective neck dissection was performed on 35 patients, and 5 patients underwent a level II to V selective neck dissection. The 1-, 3- and 5-year overall survival rates were 100, 94.6 and 73%, respectively. There was no significant difference concerning the tumor stage (P=0.69), the initial localization (P=0.64), the macroscopic aspect (P=0.65) and the management undertaken in the different centers (P=0.19). The 5-year rate of specific survival was 100%. The 1-, 3- and 5-year locoregional control rates were 96.22, 92.45 and 88.68, respectively. The oncological occurrences observed were 2 persistent diseases, 5 local recurrences, 11 second primary cancers and 0 nodal recurrences. Seven local failures were observed, all of which were controlled after a second treatment. Eleven patients presented second primary cancers; three died, two are alive with an extension of this second localization, and six are alive and free of disease. The locoregional control provided by surgery alone on T1-T2 N0 oropharyngeal cancers is as good as radiotherapy. Moreover surgery alone makes it possible to spare patients the complications and aftereffects of radiotherapy. It also makes it possible during the recurrences to operate on patients in non-irradiated areas with lower morbidity and mortality. It is all the more beneficial since it will be possible to resort to radiotherapy after surgery if need be.
Acta Oto-laryngologica | 2009
Yann Mallet; Nicolas Avalos; Anne-Marie Le Ridant; Pierre Gangloff; S. Morinière; Jean Pierre Rame; Gilles Poissonnet; Marc Makeieff; Alain Cosmidis; Emmanuel Babin; Béatrix Barry; Charles Fournier
Objectives: Squamous cell carcinoma (SCC) in young people is rare and the literature is confusing. This study was carried out to assess the demographics, clinical features, and treatment outcome in a cohort of patients aged 35 years or less with SCC of the oral tongue (SCCOT). Patients and methods: This was a multicenter retrospective study. Fifty-two patients treated between 1990 and 2000 were identified. Descriptive statistics were analyzed to assess demographic and tumor variables. Results: The WHO performance status was excellent for all patients. Thirty-seven were classified as T1–T2 and 38 were N0. All of them except one were treated with curative intent. Treatment failures were observed in 25 patients (48%). Four patients could be successfully salvaged after SCCOT recurrence or progression. The disease-free survival (DFS) was 52% at 5 years. The 5-year overall survival (OS) rate was 64%. Factors that affected the OS were invasion of the floor (p=0.009), cross over of the midline (p=0.02), positive lymph nodes (p=0.02), and the lack of disease control (p=0.0001). Conclusion: Prognosis was very poor as soon as a local failure developed. Up-front treatment should be optimized to control this rare disease. We propose producing and reporting recommendations via a concerted oncologic physician referral network.
Annals of Surgical Oncology | 2012
Juliette Thariat; Marc Hamoir; R. Garrel; Alain Cosmidis; Olivier Dassonville; Janot; C.A. Righini; Pierre-Olivier Vedrine; Jean-Michel Prades; J. Lacau-Saint-Guily; F. Jegoux; O. Malard; E. de Monès; Adil Benlyazid; René-Jean Bensadoun; B. Baujat; J.C. Merol; C. Ferron; C. Scavennec; D. Salvan; Yann Mallet; S. Morinière; S. Vergez; Olivier Choussy; G. Dollivet; Nicolas Guevara; P. Ceruse; D. De Raucourt; B. Lallemant; Georges Lawson
BackgroundThe management of the neck remains controversial in the definitive chemoradiation setting of advanced N2–3 head and neck squamous cell carcinoma. Most published data favor omission of neck dissection (ND) after complete response for N2–3 or selective ND for residual diseaseMethodsWe studied the patterns of care in the French-Belgian Groupe d’Etude des Tumeurs de la Tête Et du Cou (GETTEC) through a questionnaire-based survey.ResultsEighteen percent of institutions never performed up-front ND, 20% rarely, 40% sometimes, 14% often, and 8% systematically. Induction chemotherapy was indicated in 30% of the cases, and most ND were performed either between induction and radiation or after chemoradiation for residual disease. Response to chemoradiation was assessed by computed tomographic scan and positron emission tomography in 72% of cases. Selective ND was more common than radical ND.ConclusionsOmission of ND based on computed tomographic scan and positron emission tomography–based complete response to chemoradiation is the most common strategy for advanced nodal disease among centers. However, neck management strategies vary among institutions, and some institutions continue advocating systematic ND before irradiation. The new treatment options and the changing epidemiology, namely docetaxel-based induction chemotherapy and human papilloma virus–related head and neck squamous cell carcinoma having better response profiles and prognosis, are adding to the nonconsensual approach. The best therapeutic index in terms of neck management remains to be defined in this evolving context.
Archives of Otolaryngology-head & Neck Surgery | 2010
Olivier Choussy; C. Ferron; Pierre-Olivier Vedrine; Bruno Toussaint; Bénédicte Liétin; P. Marandas; Emmanuel Babin; Dominique De Raucourt; Emile Reyt; Alain Cosmidis; Marc Makeieff; Danièle Dehesdin
OBJECTIVE To assess the efficacy of radiotherapy in the treatment of nasoethmoidal adenocarcinoma. DESIGN Multicenter, retrospective study. SETTING Eleven French hospitals. PATIENTS The medical records of 418 patients who presented with nasoethmoidal adenocarcinoma from January 1, 1976, through December 31, 2001, were evaluated. A total of 324 patients were treated with a combination of surgery and radiotherapy, and 55 were treated with surgery only. MAIN OUTCOME MEASURES Survival rates, disease recurrence, and postoperative complications. RESULTS The 5-year Kaplan-Meier survey revealed survival rates of 64.5% for the surgery-only group and 70.8% for the combined-treatment group. In the surgery-only group, 28 patients (51%) had disease recurrence (24 local, 2 regional, and 2 distant). Of the 55 patients in the combined-treatment group, 31 patients (56%) had disease recurrence (29 local, 1 regional, and 1 distant). Immediate postoperative complications in the combined-treatment group were hemorrhages in 2 patients, meningitis in 3 patients, and cerebrospinal fluid leakage in 4 patients, but no deaths occurred. In the surgery-only group, 1 patient had meningitis, 2 had cerebrospinal fluid leaking but no hemorrhage, and 5 died postoperatively. CONCLUSION The results of this retrospective study suggest that radiotherapy can be used to treat nasoethmoidal adenocarcinoma, but its usefulness should be confirmed with further prospective studies.
Journal of Laryngology and Otology | 2006
E. Babin; V Rouleau; Pierre-Olivier Vedrine; Bruno Toussaint; D de Raucourt; O. Malard; Alain Cosmidis; M Makaeieff; Danièle Dehesdin
Annales D'otolaryngologie Et De Chirurgie Cervico-faciale | 2009
M. Foucher; Gilles Poissonnet; Jean-Pierre Rame; Bruno Toussaint; Pierre-Olivier Vedrine; Olivier Dassonville; D. de Raucourt; Alain Cosmidis
European Archives of Oto-rhino-laryngology | 2008
Olivier Choussy; Emmanuel Babin; S. Temam; Alain Cosmidis; Pierre-Olivier Vedrine; Dominique De Raucourt; Jérôme Sarini; Jean-Pierre Bessede; Pierre-Yves Lienhardt; Danièle Dehesdin
Journal of Clinical Oncology | 2016
Juliette Thariat; D. De Raucourt; P. Giraud; Frédéric Peyrade; Olivier Dassonville; Alain Cosmidis; G. Dolivet; Gilles Calais; José Santini; René-Jean Bensadoun
Cancer Radiotherapie | 2018
F. Carsuzaa; Juliette Thariat; P. Gorphe; I. Atallah; Alain Cosmidis; S. Thureau; E. de Monès; S. Servagi-Vernat; D. Tonnerre; S. Morinière; A. Dugas; O. Malard; F. Pasquier; B. Ashley; S. Vergez; Xavier Dufour